Expert perspectives on the endometrial cancer treatment landscape in light of approved therapies and drug classes.
Endometrial Carcinoma Treatment Advances
Brian Slomovitz, MD, MS, FACOG, provides a brief review of endometrial cancer relapse and corresponding therapeutic approaches.
Insight on the combination of lenvatinib and pembrolizumab in endometrial cancer, investigated between the KEYNOTE-146 and KEYNOTE-775 trials.
Practical perspectives on the optimal use of combination lenvatinib-pembrolizumab in endometrial cancer.
Brian Slomovitz, MD, MS, FACOG, shares excitement for novel and combination therapies being investigated in the endometrial cancer landscape.
Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
